Single-Fraction SBRT: A High-Value Breakthrough for Early-Stage Lung Cancer

For patients facing early-stage non-small cell lung cancer (NSCLC), the traditional path to treatment often involved invasive surgery or multiple rounds of radiation. However, a shift toward single-fraction stereotactic body radiotherapy (SBRT) is redefining the standard of care. This approach allows patients to receive an adequate, curative dose of radiation in a single treatment, offering a high-value alternative that balances clinical effectiveness with a significantly improved patient experience.

What is SBRT?

Stereotactic Body Radiotherapy (SBRT), also known as Stereotactic Ablative Radiotherapy (SABR), is a precise form of radiation therapy that delivers high doses of radiation to a targeted tumor while minimizing damage to surrounding healthy tissue. It’s recognized as a safe, effective, and curative option, particularly for patients with inoperable early-stage lung cancer ([ASCO]).

While SBRT has traditionally been delivered over several fractions (treatments), recent evidence suggests that single-fraction SBRT (SF-SBRT) provides high-value care for patients with early-stage NSCLC, reducing the burden of multiple hospital visits without compromising the dosage needed to treat the cancer.

SBRT vs. Surgery: 10-Year Outcomes

One of the most significant questions in oncology is whether radiation can truly replace surgery for operable lung cancer. Recent data presented by researchers from The University of Texas MD Anderson Cancer Center provides a definitive answer over a long-term horizon.

In a study comparing 10-year outcomes, SBRT proved comparable to surgery for patients with early-stage NSCLC. The key findings include:

• Overall Survival: At a median follow-up of 8.3 years, the overall survival rate was 69% for the SBRT cohort compared to 66% for the surgery cohort.
• Recurrence and Specific Survival: Lung cancer-specific survival and recurrence-free survival rates were similar between both groups.
• Patient Quality of Life: While surgery showed a higher rate of acute complications, the long-term quality-of-life surveys at 10 years were similar for both treatments ([MD Anderson]).

This evidence confirms that SBRT is a viable alternative even when the cancer is operable, offering the added benefits of fewer side effects and a potentially lower financial burden for the patient.

Expanding SBRT for Locally Advanced NSCLC

Beyond early-stage cases, SBRT is being integrated into more complex treatment plans for locally advanced NSCLC. A phase II multicenter trial published in The Lancet Oncology explored a combined approach: administering SBRT to the primary lung tumor followed by concurrent mediastinal chemoradiotherapy.

In this trial, patients received SBRT (50–54 Gy in 3–5 fractions) followed by standard radiotherapy to involved lymph nodes and platinum-doublet chemotherapy. Some patients also received consolidation durvalumab. The study found a 1-year progression-free survival rate of 62.7% among evaluable patients, increasing to 69.6% for those who received durvalumab ([ASCO Post]).

Key Takeaways for Patients

Frequently Asked Questions

Is SBRT as effective as surgery?

Yes. Long-term data indicates that for early-stage NSCLC, SBRT achieves similar 10-year overall survival, recurrence-free survival, and lung cancer-specific survival rates compared to surgery.

What are the advantages of single-fraction SBRT?

Single-fraction SBRT is considered high-value care because it delivers the necessary radiation dose in one session. This reduces the time, cost, and physical strain associated with multiple treatment visits.

Can SBRT be used if the cancer has spread to lymph nodes?

Yes, but it is often used as part of a broader strategy. For locally advanced NSCLC, SBRT to the primary tumor may be followed by chemoradiotherapy to the involved lymph nodes to improve outcomes.

Looking Ahead

The evolution of SBRT from a multi-fraction process to a potential single-treatment solution represents a significant leap in patient-centered care. By matching the survival outcomes of surgery while reducing complications and costs, SBRT is establishing itself as a cornerstone of modern lung cancer management. As clinical trials continue to refine these protocols, more patients can expect highly precise, less invasive, and more convenient treatment options.